Rising adoption of continuous venovenous hemofiltration (CVVH) among critical care providers, to drive CRRT industry growth during forecast period
The global Continuous Renal Replacement Therapy Market is estimated to reach USD 1.53 billion by 2022; growing at a CAGR of 7.0% during the forecast period.
Continuous Venovenous Hemofiltration (CVVH)
The widespread adoption of this modality for the treatment of AKI due to the procedural benefits poses such as high filtrate flow in CVVH that enhances the performance of solute removal, highly effective for the removal of large molecules from patients with reduced renal function or kidney failure, solutes can be removed in large quantities while easily maintaining a net zero or even a positive fluid balance in the patient. Furthermore, growing demand of continuous venovenous hemofiltration is augmented by its effectiveness in removing big molecules while maintaining a positive fluid balance in patients and a large number of ongoing research studies and clinical trials to establish the safety and efficacy profile for CRRT products.
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=246917088
Continuous venovenous hemodiafiltration to register the highest CAGR during the forecast period
Continuous Venovenous Hemodiafiltration (CVVHDF)
In this modality, blood is passed through a hemofilter and a dialysate is injected on the other side of the semi-permeable membrane, combining the filtration and dialysis processes. Positive demand growth of CVVHDF is driven by the key advantages such as better clearance of medium-sized solutes as compared to hemodialysis (due to the combination of hemofiltration with the continuous HD procedure), proper acid-base balance without additional intervention, and a significant reduction in CRRT-related phosphate depletion.
Continuous Venovenous Hemodialysis (CVVHD)
This technique removes solutes by diffusion using dialysates; replacement fluids are not required in this therapy. Effectiveness of this modality in removing small and medium-sized molecules, increasing incidences of acute renal failure and lactic acidosis are the key factors propelling the demand for CVVHD market.
Slow Continuous Ultrafiltration (SCUF)
SCUF primarily removes water from the bloodstream through ultrafiltration. This process removes excess water at a very slow ultrafiltration rate. The modest market share of this segment is mainly due to several factors such as increasing use in resolving fluid overloads, pulmonary edemas, & congestive heart failure; very low adoption owing to insufficiencies in waste clearance considering the severity of patients; and the ultrafiltrate utilized in SCUF is low, which helps in maintaining the stability of a patient’s vital signs and does not have any major side effects.
